The TKI Era in Chronic Leukemias - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34959482/
1 Hematology and Transplant Center, University "Hospital San Giovanni di Dio e Ruggi D'Aragona", 84131 Salerno, Italy. 2 Unità Operativa di Trapianto di Cellule Staminali Ematopoietiche e Terapie Cellulari, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, 80123 Napoli, Italy. 3 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Conclusion/Relevance: These tyrosine kinase inhibitors are well-tolerated, do have some associated in-class side effects that are manageable, and have remarkably improved outcomes for patients with hematologic malignancies.
• Source: Pharmaceutics
• Conclusion/Relevance: “In conclusion, we highlight CML and CLL as examples of hematological malignancies in which the TKi-based approach was transformative and has remarkably improved outcomes for patients with these diseases. The discovery of new intracellular kinase pathways that may be inhibited and the approval of further tyrosine kinase inhibitors is anticipated in the future because of the intrinsic genomic instability of hematological neoplastic cells, which may develop resistance to available therapies.”
• Targeted tyrosine kinase inhibitors have transformed CML and CLL management, with greater selectivity and higher efficacy, as well as oral alternatives and increases safety profiles. These advances have made these agents preferable to conventional chemotherapy, as well as more effective against cytogenetic variants such as CLL with del(17p).
• Undetectable MRD is now the goal of TKI-based treatment in light of a push toward discontinuation.